Error in Figure

No authors listed

Published Erratum

No authors listed. JAMA Neurol. 2020.

. 2020 Aug 1;77(8):1040.

doi: 10.1001/jamaneurol.2020.2025.

No abstract available

Erratum for

Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, McDonald CM, Zaidman CM, Morgenroth LP, Osaki H, Satou Y, Yamashita T, Hoffman EP; CINRG DNHS Investigators. Clemens PR, et al. JAMA Neurol. 2020 Aug 1;77(8):982-991. doi: 10.1001/jamaneurol.2020.1264. JAMA Neurol. 2020. PMID: 32453377 Free PMC article. Clinical Trial.

1. Clemens PR, Rao VK, Connolly AM, et al. ; CINRG DNHS Investigators . Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. Published online May 26, 2020. doi:10.1001/jamaneurol.2020.1264 - DOI - PMC - PubMed